Drug-induced nephrotoxicity are more common among infants and young children and in certain clinical situations such as underlying renal dysfunction and cardiovascular disease. Drugs can cause acute renal injury, intra-renal obstruction, interstitial nephritis, nephrotic syndrome, and acid-base and fluid electrolytes disorders. Early detection of drugs adverse effects is important to prevent progression to end-stage renal disease. Preventive measures requires knowledge of mechanisms of drug-induced nephrotoxicity, understanding patients and drug-related risk factors coupled with therapeutic intervention by correcting risk factors, assessing baseline renal function before initiation of therapy, adjusting the drug dosage and avoiding use of nephrotoxic drug combinations.
Introduction
Drug-induced nephrotoxicity is a common problem in clinical medicine and the incidence of drug-related acute kidney injury (AKI) may be as high as 60 percent (1) (2) (3) (4) . The condition can be costly and may require multiple interventions, including hospitalization (5) . This article provides a summary of the most common mechanisms of drug-induced nephrotoxicity and prevention strategies. Pathophysiologic mechanism of drug-induced nephrotoxicity is complex and often mediated through alteration of intraglomerular hemodynamics, impaired tubular secretion, inflammation, uric acid deposition, rhabdomyolysis, and thrombotic microangiopathy (6) (7) (8) . Patients with underlying renal insufficiency, defined as glomerular filtration rate (GFR) less than 60 mL/minute/1.73 m 2 , heart failure, sepsis, and intravascular depletion are particularly vulnerable to developing nephrotoxicity (Table 1) . Aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), contrast agents, and angiotensin converting enzyme inhibitors (ACEIs) are the most common cause of AKI in hospitalized patients (2) . The risk of contrast-induced nephropathy is highest in diabetics and Drug-induced nephrotoxicity chronic kidney disease diabetes (9) . "Drugs can cause nephrotoxicity by altering intraglomeular hemodynamics and decreasing GFR (ACEI, angiotensin-converting enzyme blockers [ARBs], NSAID, cyclosporine, and tacrolimus) (10) (11) (12) (13) (14) (15) . " "Certain drugs such as ampicillin, ciprofloxacin, sulfonamides, acyclovir, ganciclovir, methotrexate and triamterene are associated with crystal nephropathy (16, 17) . Crystal nephropathy may also results from the use of chemotherapy due to uric acid and calcium phosphate crystal deposition (16, 17) . " "Statins and alcohol may induce rhabdomyolysis because of a toxic effect on myocyte function, or (18) (19) (20) . Drugs most often associated with thrombotic microangiopathy include antiplatelet agents (e.g., cyclosporine, mitomycin-C, and quinine (21, 22) . " Drugs associated with tubular cell toxicity and acute interstitial nephropathy include aminoglycosides, amphotericin B, cisplatin, beta lactams, quinolones, rifampin, sulfonamides, vancomycin, acyclovir, and contrast agents (4,10,11). These agents induce renal tubular cell injury by impairing mitochondrial function and interfering with tubular transport and increasing oxidative stress and free radicals (6, 10) . Chronic use of acetaminophen, aspirin, diuretics and lithium is associated with chronic interstitial nephritis leading to fibrosis and renal scarring (11, (20) (21) (22) (23) .
Patient-related risk factors
Drug-induced renal disorders are more common in certain patients and in specific clinical situations. Infants and young children with extracellular volume depletion, sepsis, renal impairment, cardiovascular disease, diabetes, or prior exposure to radio contrast agents are at risk of developing drug nephrotoxicity.
Prevention strategies
Preventive strategies should target the safety of prescribing drug, monitoring their potential nephrotoxicity, correcting risk factors for nephrotoxicity. Before initiation the drug therapy, ensure adequate hydration and avoid the use of nephrotoxic drugs whenever possible (23) (24) (25) . Correct intravascular depletion to maintain renal perfusion before initiation of nephrotoxic agents (24, 26) . Administer drug orally and use the lowest effective dose and shortest duration of therapy whenever possible (27, 28) . Maintain drug levels within the recommended therapeutic range. Use less toxic analgesics with the lowest prostaglandins activity such as acetaminophen in patients with chronic pain and limit the duration of therapy. Discontinue or reduce the dose of nephrotoxic drug with the first sign of toxicity. Monitor renal function and serum drug concentrations during drug therapy. Use the lowest dose of low osmolar contrast agent in patients with pre-existing renal insufficiency, heart failure, and diabetes. Ensure adequate hydration with normal saline or sodium bicarbonate infusion. Consider acetazolamide and monitor GFR 24-48 hours post exposure (26) .
Estimate of renal function
As a general rule, when a new drug is prescribed, baseline renal function should be evaluated before initiating the nephrotoxic medication. Close monitoring of renal function is also essential during the course of therapy. There are several ways to estimate GFR in children. One of the easiest and more practical one is Schwartz formula using the following formula (27) : GFR (ml/min/1.73 m 2 ) = Length (cm) × k/serum creatinine (mg/dL) k = 0.35 (infants 1-4 weeks) k= 0.45 (4-52 weeks) k = 0.55 (children 1-13 years) k = 0.55 (girls 14-17 years) k = 0.70 (boys 14-18 years) Correct intravascular depletion to maintain renal perfusion before initiation of nephrotoxic agents (24) . Use analgesics with less prostaglandin activity such as aspirin and acetaminophen. Monitor renal function and serum drug concentrations during drug therapy and use the lowest effective dose and the shortest duration of therapy whenever possible (27, 28) .
